Quick Takeaways
- PHVS - Pharvaris N.V. has 13 insiders with reported activity on this page.
- Net insider value flow over the last year: -$712,840.
- Recent transaction rows are available for direct filing-level review.
- Info
- Insider Trading
- Financials
- Holders
Insider Transactions Reported by 13 Insiders of Pharvaris N.V.
- Symbol
- PHVS on Nasdaq
- Location
- Leiden
What Changed
- Buy value: ; sell value: $712,839.
- Net share flow: -25,625.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$712,840.
Buys
$0
Shares: 0
Insiders: 0
Sells
$712,840
Shares: 25,625
Insiders: 1
Net
-$712,840
Shares: -25,625
Insiders: -1
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 25,625 | $0 | $712,840 | -$712,840 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Pharvaris N.V. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Berndt Modig | Chief Executive Officer, Director | $57,198,593 | -$712,840 | -1.2% | Mixed | 16 Apr 2026 |
| Johannes Gerardus Christiaan Petrus Schikan | Director | $9,879,175 | Mixed | 17 Mar 2026 | ||
| Anne Lesage | Chief Early Development | $5,510,475 | Mixed | 18 Mar 2026 | ||
| David W. Nassif | Cfo / Clo | $3,098,125 | Mixed | 18 Mar 2026 | ||
| Annick Deschoolmeester | Chief Human Resources Officer | $2,313,825 | Mixed | 18 Mar 2026 | ||
| Peng Lu | Chief Medical Officer | $1,866,851 | Median | 16 Apr 2026 | ||
| David P. Meeker | Director | $1,629,175 | Mixed | 18 Mar 2026 | ||
| Wim Souverijns | Chief Commercial Officer | $1,377,775 | Mixed | 18 Mar 2026 | ||
| Stefan Andreas Abele | Chief Technical Ops Officer | $1,365,744 | Mixed | 27 Mar 2026 | ||
| Anna Nijdam | Principal Accounting Officer | $1,358,085 | Mixed | 14 Apr 2026 | ||
| Robert Glassman | Director | $379,175 | Mixed | 17 Mar 2026 | ||
| Elisabeth Bjork | Director | $379,175 | Mixed | 18 Mar 2026 | ||
| Viviane Monges | Director | $366,350 | Mixed | 17 Mar 2026 |
Top shareholders of Pharvaris N.V. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| GENERAL ATLANTIC, L.P. |
13F
|
Individual |
12%
|
8,031,252
|
$222,867,243 | — | 31 Dec 2025 | |
| FMR LLC |
13F
|
Company |
9.7%
|
6,399,158
|
$177,576,635 | — | 31 Dec 2025 | |
| Foresite Capital Management IV, LLC |
13F
|
Company |
7.3%
|
4,778,581
|
$132,605,623 | — | 31 Dec 2025 | |
| venBio Partners LLC |
13F
|
Company |
7.1%
|
4,639,304
|
$128,740,686 | — | 31 Dec 2025 | |
| VIKING GLOBAL INVESTORS LP |
13F
|
Company |
5.6%
|
3,653,310
|
$101,379,353 | — | 31 Dec 2025 | |
| EQT Fund Management S.a r.l. |
13F
|
Company |
5.2%
|
3,424,609
|
$95,032,900 | — | 31 Dec 2025 | |
| DEERFIELD MANAGEMENT COMPANY, L.P. |
13F
|
Company |
4.8%
|
3,126,042
|
$86,747,666 | — | 31 Dec 2025 | |
| Bain Capital Life Sciences Investors, LLC |
13F
|
Company |
4.3%
|
2,802,081
|
$77,757,748 | — | 31 Dec 2025 | |
| Berndt Modig |
3/4/5
|
Chief Executive Officer, Director |
3.1%
|
2,039,792
|
$57,198,593 | -$712,840 | 16 Apr 2026 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
2.9%
|
1,905,793
|
$52,885,757 | — | 31 Dec 2025 | |
| Commodore Capital LP |
13F
|
Company |
2.9%
|
1,889,445
|
$52,432,099 | — | 31 Dec 2025 | |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
— |
3.8%
|
2,047,620
|
$51,436,214 | $0 | 30 Jun 2025 | |
| Novo Holdings A/S |
13F
|
Company |
2.7%
|
1,750,000
|
$48,562,500 | — | 31 Dec 2025 | |
| Bain Capital Life Sciences Fund, L.P. |
13D/G
|
— |
2.5%
|
1,640,817
|
$41,020,425 | -$5,670,300 | 31 Dec 2025 | |
| Saturn V Capital Management LP |
13F
|
Company |
1.7%
|
1,140,033
|
$31,635,916 | — | 31 Dec 2025 | |
| Cormorant Asset Management, LP |
13F
|
Company |
1.7%
|
1,083,000
|
$30,053,250 | — | 31 Dec 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
1.4%
|
941,605
|
$26,130,000 | — | 31 Dec 2025 | |
| 5AM Venture Management, LLC |
13F
|
Company |
1.2%
|
797,600
|
$22,133,400 | — | 31 Dec 2025 | |
| Sofinnova Investments, Inc. |
13F
|
Company |
1.1%
|
745,169
|
$20,678,440 | — | 31 Dec 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
1.1%
|
711,625
|
$19,747,594 | — | 31 Dec 2025 | |
| BlackRock, Inc. |
13F
|
Company |
1.1%
|
708,558
|
$19,662,485 | — | 31 Dec 2025 | |
| Soleus Capital Management, L.P. |
13F
|
Company |
1.1%
|
702,052
|
$19,481,943 | — | 31 Dec 2025 | |
| Octagon Capital Advisors LP |
13F
|
Company |
1%
|
671,465
|
$18,633,154 | — | 31 Dec 2025 | |
| Kynam Capital Management, LP |
13F
|
Company |
0.98%
|
640,395
|
$17,770,961 | — | 31 Dec 2025 | |
| Rock Springs Capital Management LP |
13F
|
Company |
0.95%
|
623,402
|
$17,299,406 | — | 31 Dec 2025 | |
| Patient Square Capital LP |
13F
|
Company |
0.83%
|
542,696
|
$15,059,814 | — | 31 Dec 2025 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
0.76%
|
496,259
|
$13,771,187 | — | 31 Dec 2025 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.74%
|
486,856
|
$13,510,255 | — | 31 Dec 2025 | |
| Elmind Capital, LP |
13F
|
Company |
0.72%
|
475,750
|
$13,202,063 | — | 31 Dec 2025 | |
| Eversept Partners, LP |
13F
|
Company |
0.67%
|
439,177
|
$12,187,162 | — | 31 Dec 2025 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
0.57%
|
375,000
|
$10,406,250 | — | 31 Dec 2025 | |
| Johannes Gerardus Christiaan Petrus Schikan |
3/4/5
|
Director |
0.6%
|
395,167
|
$9,879,175 | — | 17 Mar 2026 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.4%
|
260,572
|
$7,230,873 | — | 31 Dec 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.38%
|
248,858
|
$6,905,810 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.38%
|
248,334
|
$6,891,270 | — | 31 Dec 2025 | |
| Polar Capital Holdings Plc |
13F
|
Company |
0.36%
|
237,962
|
$6,603,446 | — | 31 Dec 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.33%
|
215,188
|
$5,971,467 | — | 31 Dec 2025 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
0.31%
|
205,400
|
$5,699,850 | — | 31 Dec 2025 | |
| Kalehua Capital Management LLC |
13F
|
Company |
0.3%
|
198,772
|
$5,515,923 | — | 31 Dec 2025 | |
| Anne Lesage |
3/4/5
|
Chief Early Development |
0.34%
|
220,419
|
$5,510,475 | — | 18 Mar 2026 | |
| Tetragon Partners GP Ltd |
13F
|
Company |
0.3%
|
194,612
|
$5,400,483 | — | 31 Dec 2025 | |
| HighVista Strategies LLC |
13F
|
Company |
0.25%
|
162,370
|
$4,505,768 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.25%
|
161,499
|
$4,481,597 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.25%
|
160,910
|
$4,465,252 | — | 31 Dec 2025 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
0.24%
|
157,117
|
$4,359,997 | — | 31 Dec 2025 | |
| SCHRODER INVESTMENT MANAGEMENT GROUP |
13F
|
Company |
0.24%
|
158,019
|
$4,147,999 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0.21%
|
137,734
|
$3,822,119 | — | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.21%
|
135,069
|
$3,748,165 | — | 31 Dec 2025 | |
| Alyeska Investment Group, L.P. |
13F
|
Company |
0.19%
|
125,000
|
$3,468,750 | — | 31 Dec 2025 | |
| TD ASSET MANAGEMENT INC |
13F
|
Company |
0.18%
|
120,248
|
$3,336,882 | — | 31 Dec 2025 |
Recent Insider Transactions by Companies or Individuals for Pharvaris N.V.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Peng Lu | PHVS | Common Stock | Tax liability | -0.34% | -226 | 66,083 | 16 Apr 2026 | Direct | ||
| Berndt Modig | PHVS | Common Stock | Sale | -1.61% | $65,559 | $28.60 | -2,292 | 139,792 | 16 Apr 2026 | Direct |
| Anna Nijdam | PHVS | Common Stock | Tax liability | -1.11% | -548 | 48,940 | 11 Apr 2026 | Direct | ||
| Berndt Modig | PHVS | Common Stock | Sale | -14.1% | $647,281 | $27.74 | -23,333 | 142,084 | 09 Apr 2026 | Direct |
| Anna Nijdam | PHVS | Common Stock | Tax liability | -2.3% | -1,167 | 49,488 | 06 Apr 2026 | Direct | ||
| Anna Nijdam | PHVS | Common Stock | Tax liability | -2.25% | -1,164 | 50,655 | 01 Apr 2026 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.